Methods for characterizing and purifying the vegf receptor fusion protein
CO20260010393A2Pending Publication Date: 2026-07-31REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CO20260010393
- Authority / Receiving Office
- CO · CO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-19
- Filing Date
- 2026-07-17
- Publication Date
- 2026-07-31
Abstract
Anti-VEGF proteins, including the VEGF receptor fusion protein aflibercept, can be produced to have a low level of an aspartic protease (e.g., a low level of cathepsin D), such as less than 1 ppm of aspartic protease.
Need to check novelty before this filing date? Find Prior Art